MedPath

The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

Phase 3
Completed
Conditions
Alzheimer's Disease
Registration Number
NCT00090116
Lead Sponsor
Forest Laboratories
Brief Summary

Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
400
Inclusion Criteria
  • Clinical diagnosis of moderate to severe Alzheimer's disease;
  • ambulatory patients
Exclusion Criteria
  • folate deficiency;
  • clinically significant central nervous system disease other than Alzheimer's disease;
  • clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (34)

Ohio State University

🇺🇸

Columbus, Ohio, United States

UCI Medical Center

🇺🇸

Orange, California, United States

Piedmont Medical Research

🇺🇸

Winston Salem, North Carolina, United States

Indiana Universisty Medical Center

🇺🇸

Indianapolis, Indiana, United States

Pivotal Research Centers

🇺🇸

Peoria, Arizona, United States

Alzheimer's Research Corporation

🇺🇸

Lakehurst, New Jersey, United States

Berma Research Group

🇺🇸

Hialeah, Florida, United States

Margolin Brain Institute

🇺🇸

Fresno, California, United States

Palm Beach Neurology

🇺🇸

West Palm Beach, Florida, United States

Pharmacology Research Institute

🇺🇸

Northridge, California, United States

Palm Beach Neurological Center

🇺🇸

Palm Beach Gardens, Florida, United States

Ubhc/Umdnj

🇺🇸

Piscataway, New Jersey, United States

Neurology and Neuroscience Center of Ohio

🇺🇸

Toledo, Ohio, United States

Mood and Memory Clinic of Michigan

🇺🇸

Farmington Hills,, Michigan, United States

21st Century Neurology

🇺🇸

Phoenix, Arizona, United States

Pacific Research Network

🇺🇸

San Diego, California, United States

Affiliated Research Institute

🇺🇸

San Diego, California, United States

Nathan S. Kline Institute for Psychiatric Research

🇺🇸

Orangeburg, New York, United States

Monroe Community Hospital

🇺🇸

Rochester, New York, United States

Pioneer Pharmaceutical Research

🇺🇸

Midvale, Utah, United States

J. Gary Booker, MD

🇺🇸

Shreveport, Louisiana, United States

Upstate Clinical Research

🇺🇸

Albany, New York, United States

Neurology Clinical Research, Inc.

🇺🇸

Plantation, Florida, United States

Behavioral Medical Research of Saten Island, PC

🇺🇸

Staten Island, New York, United States

St. Louis University

🇺🇸

St. Louis, Missouri, United States

North Texas Neurology Research

🇺🇸

Wichita, Texas, United States

Baumel-Eisner Neuromedical Institute

🇺🇸

Ft. Lauderdale, Florida, United States

Joel Ross, MD

🇺🇸

Long Branch, New Jersey, United States

University of South Florida

🇺🇸

Tampa, Florida, United States

University of Colorado Health Sciences Center

🇺🇸

Denver, Colorado, United States

Yale University School of Medicine

🇺🇸

New Haven, Connecticut, United States

Lexington Clinic

🇺🇸

Lexington, Kentucky, United States

Summit Research Network

🇺🇸

Portland, Oregon, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath